Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Clancy, James
ACTIVATE, NCT04761198: A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors. May 2021 - Sep 2022 : Completion of enrollment of P1b/2 trial for solid tumors Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022 Sep 2022 - Sep 2022: Presentation of data from ACTIVATE trial for solid tumors at ESMO 2022 Initial data from P1b/2 trial in combination with Opdivo for solid tumors Nov 2021 - Nov 2021: Initial data from P1b/2 trial in combination with Opdivo for solid tumors Data from ACTIVATE trial in combination with Opdivo for solid tumors Nov 2021 - Nov 2021: Data from ACTIVATE trial in combination with Opdivo for solid tumors More	Completed	1/2	76	Europe, US	Etigilimab dosing, MPH313, Nivolumab, Opdivo	Mereo BioPharma, ICON Clinical Research	Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor	09/23	09/23
Hodgson, Ian
CRB-701-01, NCT06265727: A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors	Recruiting	1/2	420	Europe, US, RoW	CRB-701	Corbus Pharmaceuticals Inc., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.	Solid Tumor, Adult	01/27	01/27
Osborne, Roxane
No trials found